MetaCap

Adicet Bio Inc. (ACET)

NASDAQ: ACETHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.14-0.32 (-13.01%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ACET stock chart

Technical analysis

Key statistics

All statistics
Market cap
$20.03M
EPS (TTM)
-$7.53
52-week range
2.12 – 11.15
Day range
2.12 – 2.53
Volume / Avg
760.37K / 271.05K
Beta
—

52-week range

$2.12$11.15

ACET stock today

Adicet Bio (ACET) closed at $2.14 on Nov 20, down 13.01% (-$0.32), versus the S&P 500's 3.70% decline. Volume was 2.8x the average at 760.37K shares, a sign of unusually heavy trading. Shares are 80.8% below their 52-week high of $11.15, set on Nov 28, 2025 and 0.9% above the 52-week low of $2.12, near the bottom of the past year's range.

ACET is down 74.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 77.8%. Adicet Bio has posted a net loss over the last twelve months (EPS of -$7.53), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Adicet Bio

Company profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Chen Schor BA, CPA, M.B.A.
Headquarters
Boston, MA
Employees
102
IPO year
2018

Financial highlights

Full financials

Adicet Bio reported a net loss of $116.8 million, compared with a loss of $117.1 million a year earlier. Diluted earnings per share came in at -$16.95.

Adicet Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-116.80M$-117.12M$-142.66M$-69.79M$-62.00M
EPS (diluted)$-16.95$-21.33$-3.31$-1.70$-2.00

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$34.83+1527.57%

  • Strong buy 0
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $90.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.76 vs $-1.56
Surprise
-12.82%

ACET news

All ACET news

Adicet Bio peers

Health Care sector
ACET peer companies
CompanyPrice% ChgMarket capCompare
RNAZTransCode Therapeutics Inc.1.16-10.77%$20.07Mvs ACET
AARDAardvark Therapeutics Inc.0.9226-7.74%$20.20Mvs ACET
TXMDTherapeuticsMD Inc.1.71-5.52%$19.79Mvs ACET
IGCIGC Pharma Inc.0.168-8.70%$19.60Mvs ACET
CPHIChina Pharma Holdings Inc.0.4384-13.00%$18.86Mvs ACET
COCPCocrystal Pharma Inc.0.95-2.05%$18.30Mvs ACET
MRKRMarker Therapeutics Inc.1.09-17.42%$18.17Mvs ACET
CRVOCervoMed Inc.1.46+9.77%$22.09Mvs ACET

Indexes, lists and sector

Adicet Bio stock FAQ

What is Adicet Bio's stock price today?

ACET last traded at $2.14 as of Nov 20, 4:00 PM EST, down 13.01% on the day. Prices are delayed at least 15 minutes.

Does Adicet Bio pay a dividend?

No. Adicet Bio does not currently pay a regular cash dividend.

Who is Adicet Bio's CEO?

Mr. Chen Schor BA, CPA, M.B.A. is the chief executive officer of Adicet Bio Inc., which has about 102 employees.

Has ACET ever split its stock?

Yes. The most recent ACET stock split was a 1-for-16 split on Dec 30, 2025, one of 2 splits on record.

What is the ACET 52-week high?

The 52-week high for ACET is $11.15 and the 52-week low is $2.12. The stock is currently 80.8% below its high.

Compare ACET